These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 34831466)
1. Retinoid Agonists in the Targeting of Heterotopic Ossification. Pignolo RJ; Pacifici M Cells; 2021 Nov; 10(11):. PubMed ID: 34831466 [TBL] [Abstract][Full Text] [Related]
2. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial. Pacifici M Bone; 2018 Apr; 109():267-275. PubMed ID: 28826842 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent. Sinha S; Uchibe K; Usami Y; Pacifici M; Iwamoto M Bone; 2016 Sep; 90():59-68. PubMed ID: 26891836 [TBL] [Abstract][Full Text] [Related]
4. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation. Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819 [TBL] [Abstract][Full Text] [Related]
5. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP). Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535 [TBL] [Abstract][Full Text] [Related]
6. Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP). Lindborg CM; Brennan TA; Wang H; Kaplan FS; Pignolo RJ Bone; 2018 Apr; 109():153-157. PubMed ID: 28963080 [TBL] [Abstract][Full Text] [Related]
7. Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model. Pavey GJ; Qureshi AT; Tomasino AM; Honnold CL; Bishop DK; Agarwal S; Loder S; Levi B; Pacifici M; Iwamoto M; Potter BK; Davis TA; Forsberg JA Bone; 2016 Sep; 90():159-67. PubMed ID: 27368930 [TBL] [Abstract][Full Text] [Related]
8. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity. Lees-Shepard JB; Nicholas SE; Stoessel SJ; Devarakonda PM; Schneider MJ; Yamamoto M; Goldhamer DJ Elife; 2018 Sep; 7():. PubMed ID: 30226468 [TBL] [Abstract][Full Text] [Related]
10. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report. Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464 [TBL] [Abstract][Full Text] [Related]
11. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva. Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586 [TBL] [Abstract][Full Text] [Related]
12. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial. Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638 [TBL] [Abstract][Full Text] [Related]
13. Palovarotene: First Approval. Hoy SM Drugs; 2022 Apr; 82(6):711-716. PubMed ID: 35384641 [TBL] [Abstract][Full Text] [Related]
14. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Shimono K; Tung WE; Macolino C; Chi AH; Didizian JH; Mundy C; Chandraratna RA; Mishina Y; Enomoto-Iwamoto M; Pacifici M; Iwamoto M Nat Med; 2011 Apr; 17(4):454-60. PubMed ID: 21460849 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of ectopic bone formation by a selective retinoic acid receptor alpha-agonist: a new therapy for heterotopic ossification? Shimono K; Morrison TN; Tung WE; Chandraratna RA; Williams JA; Iwamoto M; Pacifici M J Orthop Res; 2010 Feb; 28(2):271-7. PubMed ID: 19725108 [TBL] [Abstract][Full Text] [Related]